This trial is conducted in Asia. The primary objective of this study is to evaluate the clinical safety profile during 26 weeks of NovoNorm® (repaglinide) and insulin analogue combination therapy in type 2 diabetes under normal clinical practice conditions in Korea while the secondary objective is to evaluate the safety and efficacy after 13 and 26 weeks of NovoNorm® and insulin analogue combination therapy in type 2 diabetes under normal clinical practice conditions in Korea.

Inclusion Criteria:

• Informed consent obtained before any study-related activities. (Study-related activities are any procedure related to recording of data according to the protocol.)
• Patients with type 2 diabetes mellitus
• Patients who are currently treated with NovoNorm® alone or in combination with metformin or TZD
• Age: at least 18 years old
• Patients who will be prescribed with insulin analogue in addition to current NovoNorm® (with/without metformin/TZD) treatment at the discretion by the Physician

Exclusion Criteria:

• Known or suspected allergy to study product(s) or related products
• Previous participation in this study. Participation is defined as screened
• Patients who have been treated with insulin preparations (including insulin analogues) previously
• Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice)
• Patients who are unlikely to comply with protocol requirements, e.g. uncooperative attitude, inability to return for the final visit
• Any other disease or condition that the Physician feels would interfere with study participation or evaluation of results

Patients who are currently treated with NovoNorm® alone or in combination with metformin or TZD (thiazolidinedione) and will be additionally prescribed with insulin analogue at the discretion of the physicians will be eligible for this study.